Fynn 🇬🇧 (@ForcedCapital) header
Fynn 🇬🇧 (@ForcedCapital) profile picture

20 | Investing since 17 £57k port Forced capital research Weekly bottleneck analysis

United Kingdom
Joined December 2025
Every vaccine is tested with crab blood. $CRL THE BOTTLENECK #6 Before a vaccine, an insulin pen or an IV drip goes anywhere near a patient, it has to be tested for bacterial toxins. The FDA-approved standard for that is the LAL test, which is made from horseshoe crab blood, and around 70 million of these tests are done every year. The crabs are caught, partly drained of their blue blood and released, which is about as niche as a supply chain gets. WHO MAKES MONEY Charles River ($CRL) is one of the FDA-licensed LAL makers. It also sells a synthetic version called Trillium that doesn’t need any crab at all. THE CATCH The synthetic route now has a proper rulebook. A dedicated recombinant testing chapter was approved in July 2024 and published in 2025. It sits alongside the old LAL standard rather than replacing it, but it means this bottleneck is slowly being engineered away. MY TAKE What I like is that Charles River sits on both sides, so whether labs stick with crab blood or switch to the synthetic one, they’re selling the test either way. The risk is that it turns into a commodity once anyone can make the synthetic version.
101
$NBIS Q3: Revenue BEAT 🟢 $980.8M vs $907M expected (+8%)
 +68% QoQ | +571% YoY Revenue ran ahead of the Street, and capacity is still the bottleneck, not demand. The print that decides the stock is exit ARR vs the $7–9B year-end target.
318
This is such a wild price for $NVDA You’d be silly not to buy here.
130
This premarket is wild. The come back is on!
2
5
356
Yea hold tight or something.
116
Before uranium can go into a reactor it has to be turned into a gas, and America only has one plant that does it. It’s in Metropolis, Illinois, and it’s owned by $SOLS which was spun out of Honeywell last year. It’s aiming to make over 10,000 tonnes this year, has a backlog of more than $2bn, and the US government is helping fund the expansion. Most of Solstice is actually refrigerants, so this isn’t a pure nuclear play. But if the US is serious about quadrupling nuclear power, every bit of new fuel has to go through this one place first.
2
522
Trump can't sleep at night without this company. $PKE WHO THEY ARE Park Aerospace $PKE make the heat shield material that lines the rocket motor of the PAC-3 MSE interceptor, and in its words it’s “sole source qualified” for it. They basically work like oven gloves on the inside of a rocket, made to burn slowly so the motor doesn’t melt mid flight. THE BOTTLENECK The special fabric behind it is made by ArianeGroup in France, and Park is its exclusive North American distributor. In July they signed a term sheet for a new US plant where 100% of the output goes to Park. WHY IT MATTERS Lockheed and the Pentagon want PAC-3 production going from roughly 600 a year to 2,000 by the end of 2030. THE CATCH It’s around a $566m company on roughly 36x earnings, missile sales were only $5.7m last quarter, and that US plant isn’t expected to feed purchases until 2030, so it still hangs on one supplier in France. MY TAKE What surprised me most was zero long term debt and $115m of cash. Although, currently I'm waiting for the definitive Ariane deal.
166
Who do the world’s big scanner makers turn to when they need a crystal they can’t grow themselves? Turns out it’s a tiny AIM company from County Durham. WHO THEY ARE Kromek $KMK makes CZT, cadmium zinc telluride, a crystal that turns every X-ray that hits it into an electrical signal. It’s the heart of photon counting CT, the next upgrade in hospital scanners. It’s like swapping a camera that sees a blurry glow, for one that counts every single photon. THE BOTTLENECK Siemens bought Acrorad, Canon bought Redlen, and Kromek now says it's “the only independent commercial scale producer of CZT globally”. Siemens Healthineers paid $37.5m to license Kromek’s know how and take 15 of its 174 furnaces. THE CATCH It’s worth roughly £37m and sits near its 52-week low around 5.5p, it’s using an HSBC credit line for working capital, and that Siemens deal is basically teaching a giant customer to make its own crystals. Revenue was £27.1m last year, but over a third of that was the one off Siemens money. MY TAKE My question: is being the last independent one a moat, or just a takeover waiting to happen?
3
198
Anthropic, filed publicly for its IPO yesterday, it's going on the Nasdaq under the ticker $ANT with an arrival of mid november. The revenue growth is impressive: $16.3bn in the first half of this year, up from $1.2bn a year earlier. But the number that shocked me was the valuation. Reports say it’s targeting somewhere between $1.5 and $2 trillion, for a company that lost $80.7bn in the same six months (although about $72bn of that was a one off accounting charge). It’s an incredible business, but it isn’t a bottleneck in the way I usually look at them, as there are other AI labs fighting for the same customers. I never buy IPOs on day one as there's sometimes a period of uncertainty and repricing, it's pretty much just a gamble. $SPCX is a great example. Unfortunately, I do think if this event is not played perfectly we will see a lo tof uncertainty in the markets.
3
135
Nearly every US missile and rocket booster needs a chemical called ammonium perchlorate, which is basically the oxygen supply that lets solid rocket fuel burn. And the main American supplier is a plant in Utah owned by $NEU NewMarket, a company that mostly sells additives for engine oil. In its own annual report it says the overseas producers in France, Japan, China and India aren’t qualified for most US military and NASA programmes. It’s also spending $100m to grow capacity by more than 50%. The bit I find funny is that you’d never know any of this from the share price, because it’s priced like a lubricant company.
1
2
172